Scholarlink

<p>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) poses a critical global threat, necessitating precise molecular surveillance. This study investigated the clonal diversity and resistance mechanisms of <i>A. baumannii</i> in Northwestern Iran. A total of 89 non-duplicate isolates were collected from ICU patients (May 2024–June 2025). Susceptibility testing was performed per CLSI guidelines, and resistance determinants (<i>bla</i><sub>OXA−23</sub>, <i>bla</i><sub>PER</sub>, <i>bla</i><sub>TEM</sub>, etc.) were screened by PCR. Clonal lineages were identified using Pasteur Multi-Locus Sequence Typing (MLST). The isolates exhibited alarming resistance rates, with 95.5% classified as CRAB and 91% as extensively drug-resistant (XDR). The <i>bla</i><sub>OXA−23</sub> carbapenemase was the predominant resistance driver (95.5%). MLST analysis of representative isolates identified ST2 (12/16, 75%) as the dominant lineage strictly within the purposively selected subset. Significantly, this study provides the first report of rare sequence types ST124 and ST586 in Iran. While <i>bla</i><sub>OXA−23</sub>-producing ST2 remains the primary endemic threat, the emergence of these rare singletons acts as an early warning indicator for the introduction of previously undetected genetic reservoirs. Colistin retained the highest in vitro activity (97.8% intermediate/colistin-active), emphasizing its crucial role as a last-resort therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rare ST124 and ST586 lineages co-circulate with the dominant ST2 clone among extensively drug-resistant Acinetobacter baumannii in Iran

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Shaho Menbari,
  • Himen Salimizand,
  • Daem Roshani,
  • Fariba Lahoorpour

摘要

Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a critical global threat, necessitating precise molecular surveillance. This study investigated the clonal diversity and resistance mechanisms of A. baumannii in Northwestern Iran. A total of 89 non-duplicate isolates were collected from ICU patients (May 2024–June 2025). Susceptibility testing was performed per CLSI guidelines, and resistance determinants (blaOXA−23, blaPER, blaTEM, etc.) were screened by PCR. Clonal lineages were identified using Pasteur Multi-Locus Sequence Typing (MLST). The isolates exhibited alarming resistance rates, with 95.5% classified as CRAB and 91% as extensively drug-resistant (XDR). The blaOXA−23 carbapenemase was the predominant resistance driver (95.5%). MLST analysis of representative isolates identified ST2 (12/16, 75%) as the dominant lineage strictly within the purposively selected subset. Significantly, this study provides the first report of rare sequence types ST124 and ST586 in Iran. While blaOXA−23-producing ST2 remains the primary endemic threat, the emergence of these rare singletons acts as an early warning indicator for the introduction of previously undetected genetic reservoirs. Colistin retained the highest in vitro activity (97.8% intermediate/colistin-active), emphasizing its crucial role as a last-resort therapy.